TRAX Stock Forecast & Price Target

First Tracks is well positioned because its lead asset ANB033 has already produced statistically significant, clinically meaningful Phase Ib celiac disease data, including a +0.49 treatment difference in villous height:crypt depth ratio (p=0.009) and symptom improvement, while Cohort 2 enrollment is complete and topline data remains on track for 1Q27. The investment case is further strengthened by a broad, high-upside pipeline-in-a-product strategy across celiac disease, eosinophilic esophagitis, and vitiligo, with management expecting a late-stage celiac program in 2027 and additional Phase II or topline catalysts in 1H27 and 3Q27. Valuation support also looks compelling, with estimates of about $44/share from ANB033 in celiac disease, $41/share in EoE, $21/share in vitiligo, and anticipated YE27 net cash of roughly $4/share, all against a backdrop of strong external validation for the CD122/IL-15 target.

First Tracks is fundamentally challenged by an early-stage pipeline that has yet to prove clinical or commercial viability, with rosnilimab, ANB033, and ANB101 all exposed to trial failure, safety issues, or weak readthrough from competitors. The company also faces a high financing burden because it is not cash flow positive, meaning additional public or private capital raises could dilute shareholders if cash burn exceeds expectations. With competition intensifying across CD122 and BDCA2 mechanisms and no assurance of a rosnilimab partnership, the risk-reward profile remains skewed to the downside.